Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

Blue Cross Blue Shield Illinois to cover Trovera liquid biopsy tests

Published 18 August 2016

Trovagene, a developer of circulating tumor DNA (ctDNA) molecular diagnostics, announced that it has signed an in-network provider agreement with the healthcare network Blue Cross Blue Shield of Illinois (BCBSIL) establishing health benefit access to the full line of Trovagene's tests and services.

"The agreement with BCBSIL takes us a step further in the execution of our access and reimbursement strategy that includes establishing relationships with leading national and regional payors," said Bill Welch, Chief Executive Officer of Trovagene.

 "We are looking forward to offering oncologists and their patient's access to our Trovera™ urine and blood based liquid biopsy tests and enabling personalized cancer care."

Trovagene now has contracts with payors covering approximately 168 million lives.  Increasing patient access by contracting with payors is one of the critical strategic components that support the adoption of Trovagene's clinical testing in late-stage solid tumor cancers.

With 8 million members, BCBSIL, a division of Health Care Service Corporation, a Mutual Legal Reserve Company, is the largest health insurance company in Illinois.

Begun in 1936 in Chicago, BCBSIL remains member owned rather than publicly traded, and is committed to promoting the health and wellness of its members and its communities, fostering greater access to care, and working to lower the overall cost of care while improving care quality and patient outcomes.



Source: Company Press Release